Literature DB >> 23503840

Transforming growth factor-β1 gene mutations and phenotypes in pediatric patients with Camurati‑Engelmann disease.

Chun Wang1, Bao-Hong Zhang, Yu-Juan Liu, Yun-Qiu Hu, Jin-Wei He, Zhen-Lin Zhang.   

Abstract

The aim of the present study was to investigate the clinical characteristics and major causative gene in pediatric patients with Camurati‑Engelmann disease (CED). Biochemical and radiographic examinations, bone scintigraphy and genetic analyses were performed in two affected males and their parents. The two patients experienced waddling gait, muscular weakness and growth developmental delay. X-ray radiography revealed typical fusiform thickening of the diaphyseal portions of the long bones. The abnormal uptake of tracer Tc-99m was visualized in the skull and both sides of the upper humeri, ulnas, radii, femurs and tibias using bone scintigraphy. Serum levels of the bone formation marker procollagen type I N-terminal propeptide (PINP) and the bone resorption marker β‑isomerized C-terminal cross-linked telopeptide of type I collagen (β-CTX) in the 6-year-old patient were significantly increased compared with the normal value range, while only the β-CTX levels were elevated in the 16-year-old patient. A heterozygous missense mutation p.Arg218Cys in exon 4 of the transforming growth factor β1 (TGFβ1) gene was detected in the two patients, while their parents had normal wild‑type genotypes. In conclusion, the p.Arg218Cys mutation was shown to contribute to the clinical phenotypes in two pediatric patients with CED. The results of this study suggest that abnormal bone turnover marker levels, typical radiological findings and mutations in the TGFβ1 gene are three important factors in the diagnosis of sporadic CED cases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23503840     DOI: 10.3892/mmr.2013.1367

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  3 in total

1.  Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease.

Authors:  Giampiero I Baroncelli; Elena Ferretti; Cecilia M Pini; Benedetta Toschi; Rita Consolini; Silvano Bertelloni
Journal:  Mol Syndromol       Date:  2017-09-09

2.  Clinical characteristics and identification of a novel TGFB1 variant in three unrelated Chinese families with Camurati-Engelmann disease.

Authors:  Xiao-Hui Tao; Xing-Guang Yang; Zi-Yuan Wang; Yang Xu; Xiao-Yun Lin; Tian Xu; Zhen-Lin Zhang; Hua Yue
Journal:  Mol Genet Genomic Med       Date:  2022-03-21       Impact factor: 2.473

3.  Clinical diagnosis and mutation analysis of a Chinese family with Camurati-Engelmann disease.

Authors:  Yong Chen; Wanqin Xie; Feng Hu; Jia Chen; Hexin Zheng; Haiyan Zhou; Bin Ni; Wanmeng Li; Jianda Zhou
Journal:  Mol Med Rep       Date:  2016-12-12       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.